|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
84,758,000 |
Market
Cap: |
89.84(M) |
Last
Volume: |
442,324 |
Avg
Vol: |
441,063 |
52
Week Range: |
$0.8931 - $3.24 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Oncolytics Biotech is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers. Co.'s primary product, pelareorep, is an immuno-oncology viral-agent that may be a treatment for certain types of cancer and may be an alternative to or used in combination with existing cytotoxic or cytostatic therapies. Co.'s clinical development program for pelareorep centers on main immunotherapy combinations. Immunotherapy combinations in which pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and/or targeted therapies.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|